| 0.5339 0 (0%) | 01-18 15:56 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.68 | 1-year : | 0.8 |
| Resists | First : | 0.59 | Second : | 0.68 |
| Pivot price | 0.5  |
|||
| Supports | First : | 0.44 | Second : | 0.35 |
| MAs | MA(5) : | 0.5 | MA(20) : | 0.48 |
| MA(100) : | 0.74  |
MA(250) : | 1.81 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 52.1 |
D(3) : | 56.4 |
| RSI | RSI(14): 50.2 | |||
| 52-week | High : | 6.09 | Low : | 0.35 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AYLA ] has closed above bottom band by 44.0%. Bollinger Bands are 76.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 57 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.5 - 0.51 | 0.51 - 0.51 |
| Low: | 0.5 - 0.5 | 0.5 - 0.5 |
| Close: | 0.5 - 0.5 | 0.5 - 0.51 |
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Thu, 19 Jan 2023
Advaxis and Ayala Pharmaceuticals Complete Merger - GlobeNewswire
Wed, 16 Nov 2022
Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid ... - GlobeNewswire
Wed, 19 Oct 2022
Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement - GlobeNewswire
Mon, 12 Sep 2022
Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid ... - GlobeNewswire
Wed, 24 Aug 2022
Should You Buy Ayala Pharmaceuticals Inc (AYLA) Stock on Wednesday? - InvestorsObserver
Tue, 12 May 2020
Ayala Pharmaceuticals Announces Closing of Initial Public Offering - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 6.9e+006 (%) |
| Held by Institutions | 29.7 (%) |
| Shares Short | 149 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.739e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 166.3 % |
| Return on Equity (ttm) | -78.3 % |
| Qtrly Rev. Growth | 1.73e+006 % |
| Gross Profit (p.s.) | -42.92 |
| Sales Per Share | -81.34 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 1.69 |
| Dividend | 0 |
| Forward Dividend | 48230 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|